Hayashi H, Nadal E, Gray JE, Ardizzoni A, Caria N, Puri T, Grohe C (2022) Overall treatment strategy for patients with metastatic NSCLC with activating EGFR mutations. Clin Lung Cancer 23:e69–e82. https://doi.org/10.1016/j.cllc.2021.10.009

Article  CAS  PubMed  Google Scholar 

Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327–3334. https://doi.org/10.1200/JCO.2012.44.2806

Article  CAS  PubMed  Google Scholar 

Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15:213–222. https://doi.org/10.1016/S1470-2045(13)70604-1

Article  CAS  PubMed  Google Scholar 

Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL (2015) Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 16:830–838. https://doi.org/10.1016/S1470-2045(15)00026-1

Article  CAS  PubMed  Google Scholar 

Park K, Tan EH, O’Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L (2016) Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 17:577–589. https://doi.org/10.1016/S1470-2045(16)30033-X

Article  CAS  PubMed  Google Scholar 

Paz-Ares L, Tan EH, O’Byrne K, Zhang L, Hirsh V, Boyer M, Yang JC, Mok T, Lee KH, Lu S, Shi Y, Lee DH, Laskin J, Kim DW, Laurie SA, Kölbeck K, Fan J, Dodd N, Märten A, Park K (2017) Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol 28:270–277. https://doi.org/10.1093/annonc/mdw611

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC, Investigators FLAURA (2020) Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382:41–50. https://doi.org/10.1056/NEJMoa1913662

Article  CAS  PubMed  Google Scholar 

Cho BC, Chewaskulyong B, Lee KH, Dechaphunkul A, Sriuranpong V, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cheng Y, Cho EK, Voon PJ, Lee JS, Mann H, Saggese M, Reungwetwattana T, Ramalingam SS, Ohe Y (2019) Osimertinib versus standard of care EGFR TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset. J Thorac Oncol 14:99–106. https://doi.org/10.1016/j.jtho.2018.09.004

Article  CAS  PubMed  Google Scholar 

Chu MP, Ghosh S, Chambers CR, Basappa N, Butts CA, Chu Q, Fenton D, Joy AA, Sangha R, Smylie M, Sawyer MB (2015) Gastric acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. Clin Lung Cancer 16:33–39. https://doi.org/10.1016/j.cllc.2014.07.005

Article  CAS  PubMed  Google Scholar 

Lam LH, Capparelli EV, Kurzrock R (2016) Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib. Cancer Chemother Pharmacol 78:427–432. https://doi.org/10.1007/s00280-016-3087-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen YM, Lai CH, Chang HC, Chao TY, Tseng CC, Fang WF, Wang CC, Chung YH, Wang YH, Su MC, Liu SF, Huang KT, Chen HC, Chang YC, Lin MC (2016) pH-regulating drug use and de novo brain metastases in patients with epidermal growth factor receptor-mutant non-small cell lung cancer who were treated using first-line first-generation epidermal growth factor receptor tyrosine kinase inhibitors. PLoS One 11:e0149722. https://doi.org/10.1371/journal.pone.0149722

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fang YH, Yang YH, Hsieh MJ, Hung MS, Lin YC (2019) Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment—a nationwide population-based study. Cancer Manag Res 11:8539–8546. https://doi.org/10.2147/CMAR.S222278

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee CH, Shen MC, Tsai MJ, Chang JS, Huang YB, Yang YH, Hsieh KP (2022) Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib. Sci Rep 12:7002. https://doi.org/10.1038/s41598-022-10938-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu ZY, Li JL (2019) Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. Onco Targets Ther 12:5467–5484. https://doi.org/10.2147/OTT.S194870

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakao K, Kobuchi S, Marutani S, Iwazaki A, Tamiya A, Isa S, Okishio K, Kanazu M, Tamiya M, Hirashima T, Imai K, Sakaeda T, Atagi S (2019) Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer. Sci Rep 9:18202. https://doi.org/10.1038/s41598-019-54804-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vishwanathan K, Dickinson PA, Bui K, Cassier PA, Greystoke A, Lisbon E, Moreno V, So K, Thomas K, Weilert D, Yap TA, Plummer R (2018) The effect of food or omeprazole on the pharmacokinetics of osimertinib in patients with non-small-cell lung cancer and in healthy volunteers. J Clin Pharmacol 58:474–484. https://doi.org/10.1002/jcph.1035

Article  CAS  PubMed  Google Scholar 

Ho MC, Chung YS, Lin YC, Hung MS, Fang YH (2022) Combination use of first-line afatinib and proton-pump inhibitors reduces overall survival among patients with EGFFR mutant lung cancer. Onco Targets Ther 15:1573–1582. https://doi.org/10.2147/OTT.S387165

Article  CAS  PubMed  PubMed Central  Google Scholar 

Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Otani K, Hibino M, Horiuchi S, Fukui T, Fukai R, Chihara Y, Iwase A, Yamada N, Tamura Y, Harada H, Shinozaki N, Tsuya A, Fukuoka M, Minami H (2023) Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01). Jpn J Clin Oncol 54(3):319–328. https://doi.org/10.1093/jjco/hyad162

Article  Google Scholar 

Shimoyama R, Imamura Y, Uryu K, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Ohtani K, Shinozaki N, Minami H (2022) Real-world outcomes of systemic therapy in Japanese patients with cancer (Tokushukai REAl-World Data project: TREAD): study protocol for a nationwide cohort study. Healthcare (Basel, Switzerland) 10:2146. https://doi.org/10.3390/healthcare10112146

Article  PubMed  Google Scholar 

National Cancer Registry (Ministry of Health, Labour and Welfare), tabulated by Cancer Information Service, National Cancer Center, Japan. https://ganjoho.jp/reg_stat/statistics/data/dl/en.html. Accessed 28 Feb 2023

Akaike H (1973) Information theory and an extension of the maximum likelihood principle. Institute of Statistical Mathematics, pp 199–213

Saito Y, Takekuma Y, Kobayashi M, Shinagawa N, Shimizu Y, Kinoshita I, Dosaka-Akita H, Iseki K, Sugawara M (2021) Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer. Eur J Clin Pharmacol 77:381–388. https://doi.org/10.1007/s00228-020-03013-9

Article  CAS  PubMed  Google Scholar 

Su VY, Yang KY, Huang TY, Hsu CC, Chen YM, Yen JC, Chou YC, Chang YL, He CH (2020) The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer. Sci Rep 10:14965. https://doi.org/10.1038/s41598-020-71583-w

Article  PubMed  PubMed Central  Google Scholar 

Zenke Y, Yoh K, Matsumoto S, Umemura S, Niho S, Ohmatsu H, Goto K, Ohe Y (2016) Clinical impact of gastric acid-suppressing medication use on the efficacy of erlotinib and gefitinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. Clin Lung Cancer 17:412–418. https://doi.org/10.1016/j.cllc.2016.01.006

Article  CAS  PubMed  Google Scholar 

Li J, Nickens D, Wilner K, Tan W (2021) Evaluation of the effect of proton pump inhibitors on the efficacy of dacomitinib and gefitinib in patients with advanced non-small cell lung cancer and EGFR-activating mutations. Oncol Ther 9:525–539. https://doi.org/10.1007/s40487-021-00156-2

Article  PubMed  PubMed Central  Google Scholar 

Sachs G, Shin JM, Vagin O, Lambrecht N, Yakubov I, Munson K (2007) The gastric H, K ATPase as a drug target: past, present, and future. J Clin Gastroenterol 41(Suppl 2):S226–S242. https://doi.org/10.1097/MCG.0b013e31803233b7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Asano S (2011) Molecular basis of gastric acid secretion in parietal cells. Membrane 36:278–285. https://doi.org/10.5360/membrane.36.278

Article  CAS  Google Scholar 

Roche VF (2006) The chemically elegant proton pump inhibitors. Am J Pharm Educ 70:101. https://doi.org/10.5688/aj7005101

Article  PubMed  PubMed Central  Google Scholar 

Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11:217–227. https://doi.org/10.1016/j.ccr.2006.12.017

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stamos J, Sliwkowski MX, Eigenbrot C (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277:46265–46272. https://doi.org/10.1074/jbc.M207135200